Semi-permanent transcorneal filter support and in vivo surgical implantation technique for open-angle glaucoma treatment

2019 ◽  
Vol 21 (4) ◽  
Author(s):  
Brett Collar ◽  
Gabriel Simón ◽  
Quan Yuan ◽  
Sui Shen ◽  
Pedro Irazoqui
2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Daiva Paulaviciute-Baikstiene ◽  
Renata Vaiciuliene ◽  
Vytautas Jasinskas ◽  
Ingrida Januleviciene

Purpose. To evaluate thein vivochanges in Schlemm’s canal (SC) and the trabecular meshwork (TM) in patients with primary open-angle glaucoma (POAG) after phacocanaloplasty using anterior segment optical coherence tomography (AS-OCT).Methods. Ten eyes of nine patients with POAG (6 men and 3 women) who underwent phacocanaloplasty. Preoperative and postoperative visual acuity (VA), intraocular pressure (IOP), and use of glaucoma medications were evaluated. The main outcome measures were the area of SC and TM thickness assessed using AS-OCT before and 12 months after surgery.Results. We found statistically significant reduction in IOP (from 26.4 (8.6) mmHg to 12.9 (2.5) (p<0.05) mmHg), increase in VA from 0.7 (0.4) to 0.9 (0.2), and decrease in glaucoma medication from 2.6 (1.2) to 1.1 (1.3) at 12 months postoperatively. There was a significant increase in the SC area (3081.7 (842.8) μm2versus 5098.8 (1190.5) μm2,p<0.001) and a decrease in mean TM thickness (91.2 (18.6) μm versus 81.3 (15.1) μm,p=0.001) after surgery. We found negative correlations between SC area and IOP before surgery (r=-0.67,p=0.03) and also between SC area before and IOP reduction 12 months after the phacocanaloplasty (r=-0.80,p=0.005).Conclusions. Our results showed statistically significant dilation of SC area and reduction of TM thickness after phacocanaloplasty in POAG patients. The degree of SC expansion was related to the IOP decrease.


2012 ◽  
Vol 96 (9) ◽  
pp. 1180-1184 ◽  
Author(s):  
David C Musch ◽  
Takayuki Shimizu ◽  
Leslie M Niziol ◽  
Brenda W Gillespie ◽  
L Frank Cashwell ◽  
...  

Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins

The United Kingdom Glaucoma Treatment Study (UKGTS) was a randomized, triple-masked, placebo-controlled trial comparing topical latanoprost, a prostaglandin analogue, with placebo in patients with newly diagnosed, previously untreated open-angle glaucoma (OAG). Compared to placebo, the latanoprost group showed a large, statistically significant reduction in the rate of glaucomatous visual field deterioration by 24 months. The UKGTS was the first placebo-controlled trial to show visual field preservation through lowering of intraocular pressure with topical drugs in patients with OAG, and the first to show the visual field–preserving effect of a topical prostaglandin analogue.


Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins

The Collaborative Initial Glaucoma Treatment Study (CIGTS) was a randomized clinical trial to determine whether patients with newly diagnosed open-angle glaucoma (OAG) were managed better by initial treatment with medications (using a stepped regimen of medications starting initially with a topical beta-blocker) or by immediate filtration surgery (trabeculectomy with or without 5-fluorouracil). Although the surgery group achieved a lower mean intraocular pressure (IOP) than the medication group, both groups had similarly low rates of visual field progression. Three measures of IOP fluctuation over extended time, the range of IOP, the standard deviation of IOP, and the maximum IOP, seem to play an important role in visual field progression The results showed that more aggressive treatment was warranted when undue elevation or variation in IOP measures is observed.


2017 ◽  
Vol 58 (13) ◽  
pp. 6000 ◽  
Author(s):  
Viney Gupta ◽  
Abadh K. Chaurasia ◽  
Shikha Gupta ◽  
Bhavya Gorimanipalli ◽  
Ajay Sharma ◽  
...  

Author(s):  
Aina Liz A. Cesar ◽  
Larissa Caldeira Navarro ◽  
Rachel Oliveira Castilho ◽  
Gisele Assis Castro Goulart ◽  
Giselle Foureaux ◽  
...  

2016 ◽  
Vol 25 (12) ◽  
pp. 946-951 ◽  
Author(s):  
Noa Geffen ◽  
Michael Mimouni ◽  
Mark Sherwood ◽  
Ehud I. Assia

Sign in / Sign up

Export Citation Format

Share Document